Cargando…
Liver kinase B1 in exosomes inhibits immune checkpoint programmed death ligand 1 and metastatic progression of intrahepatic cholangiocarcinoma
The increasing morbidity and high mortality of intrahepatic cholangiocarcinoma (ICC) has led to the urgent need for new diagnostics and therapeutics. Liver kinase B1 (LKB1) exerts a tumor suppressor role in multiple malignances, while its regulatory role in exosomes secreted by ICC cells is obscure....
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9350976/ https://www.ncbi.nlm.nih.gov/pubmed/35856436 http://dx.doi.org/10.3892/or.2022.8367 |
_version_ | 1784762336436813824 |
---|---|
author | Liu, Zhuo Zhou, Kunyan Zeng, Jian Zhou, Xin Li, Huanyu Peng, Ke Liu, Xiang Li, Feng Jiang, Bin Zhao, Ming Ma, Tiexiang |
author_facet | Liu, Zhuo Zhou, Kunyan Zeng, Jian Zhou, Xin Li, Huanyu Peng, Ke Liu, Xiang Li, Feng Jiang, Bin Zhao, Ming Ma, Tiexiang |
author_sort | Liu, Zhuo |
collection | PubMed |
description | The increasing morbidity and high mortality of intrahepatic cholangiocarcinoma (ICC) has led to the urgent need for new diagnostics and therapeutics. Liver kinase B1 (LKB1) exerts a tumor suppressor role in multiple malignances, while its regulatory role in exosomes secreted by ICC cells is obscure. In the present study, exosomes were extracted from cell culture supernatants of RBE and HCCC-9810 ICC cells as well as plasma of patients with ICC by ultracentrifugation and the morphology of exosomes was identified by transmission electron microscopy. Notably, compared with that of intracellular LKB1, the protein level of exosomal LKB1 was decreased. Silencing intracellular LKB1 increased the protein levels of programmed death ligand 1 (PD-L1), Slug and phosphorylated-AKT in exosomes, accompanied by decreased expression levels of exosomal LKB1. Exosomes with lower protein levels of LKB1 promoted the expression of the immune checkpoint PD-L1, malignant phenotypes of ICC cells in vitro, and cancer metastasis in vivo. Moreover, the low level of exosomal LKB1 in plasma was tightly associated with the poor prognosis of patients with ICC. Collectively, exosomal LKB1 inhibits the immune checkpoint PD-L1 and metastasis of ICC cells. These findings may provide new methods for the diagnosis and immune therapy of ICC. |
format | Online Article Text |
id | pubmed-9350976 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-93509762022-08-09 Liver kinase B1 in exosomes inhibits immune checkpoint programmed death ligand 1 and metastatic progression of intrahepatic cholangiocarcinoma Liu, Zhuo Zhou, Kunyan Zeng, Jian Zhou, Xin Li, Huanyu Peng, Ke Liu, Xiang Li, Feng Jiang, Bin Zhao, Ming Ma, Tiexiang Oncol Rep Articles The increasing morbidity and high mortality of intrahepatic cholangiocarcinoma (ICC) has led to the urgent need for new diagnostics and therapeutics. Liver kinase B1 (LKB1) exerts a tumor suppressor role in multiple malignances, while its regulatory role in exosomes secreted by ICC cells is obscure. In the present study, exosomes were extracted from cell culture supernatants of RBE and HCCC-9810 ICC cells as well as plasma of patients with ICC by ultracentrifugation and the morphology of exosomes was identified by transmission electron microscopy. Notably, compared with that of intracellular LKB1, the protein level of exosomal LKB1 was decreased. Silencing intracellular LKB1 increased the protein levels of programmed death ligand 1 (PD-L1), Slug and phosphorylated-AKT in exosomes, accompanied by decreased expression levels of exosomal LKB1. Exosomes with lower protein levels of LKB1 promoted the expression of the immune checkpoint PD-L1, malignant phenotypes of ICC cells in vitro, and cancer metastasis in vivo. Moreover, the low level of exosomal LKB1 in plasma was tightly associated with the poor prognosis of patients with ICC. Collectively, exosomal LKB1 inhibits the immune checkpoint PD-L1 and metastasis of ICC cells. These findings may provide new methods for the diagnosis and immune therapy of ICC. D.A. Spandidos 2022-07-15 /pmc/articles/PMC9350976/ /pubmed/35856436 http://dx.doi.org/10.3892/or.2022.8367 Text en Copyright: © Liu et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Articles Liu, Zhuo Zhou, Kunyan Zeng, Jian Zhou, Xin Li, Huanyu Peng, Ke Liu, Xiang Li, Feng Jiang, Bin Zhao, Ming Ma, Tiexiang Liver kinase B1 in exosomes inhibits immune checkpoint programmed death ligand 1 and metastatic progression of intrahepatic cholangiocarcinoma |
title | Liver kinase B1 in exosomes inhibits immune checkpoint programmed death ligand 1 and metastatic progression of intrahepatic cholangiocarcinoma |
title_full | Liver kinase B1 in exosomes inhibits immune checkpoint programmed death ligand 1 and metastatic progression of intrahepatic cholangiocarcinoma |
title_fullStr | Liver kinase B1 in exosomes inhibits immune checkpoint programmed death ligand 1 and metastatic progression of intrahepatic cholangiocarcinoma |
title_full_unstemmed | Liver kinase B1 in exosomes inhibits immune checkpoint programmed death ligand 1 and metastatic progression of intrahepatic cholangiocarcinoma |
title_short | Liver kinase B1 in exosomes inhibits immune checkpoint programmed death ligand 1 and metastatic progression of intrahepatic cholangiocarcinoma |
title_sort | liver kinase b1 in exosomes inhibits immune checkpoint programmed death ligand 1 and metastatic progression of intrahepatic cholangiocarcinoma |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9350976/ https://www.ncbi.nlm.nih.gov/pubmed/35856436 http://dx.doi.org/10.3892/or.2022.8367 |
work_keys_str_mv | AT liuzhuo liverkinaseb1inexosomesinhibitsimmunecheckpointprogrammeddeathligand1andmetastaticprogressionofintrahepaticcholangiocarcinoma AT zhoukunyan liverkinaseb1inexosomesinhibitsimmunecheckpointprogrammeddeathligand1andmetastaticprogressionofintrahepaticcholangiocarcinoma AT zengjian liverkinaseb1inexosomesinhibitsimmunecheckpointprogrammeddeathligand1andmetastaticprogressionofintrahepaticcholangiocarcinoma AT zhouxin liverkinaseb1inexosomesinhibitsimmunecheckpointprogrammeddeathligand1andmetastaticprogressionofintrahepaticcholangiocarcinoma AT lihuanyu liverkinaseb1inexosomesinhibitsimmunecheckpointprogrammeddeathligand1andmetastaticprogressionofintrahepaticcholangiocarcinoma AT pengke liverkinaseb1inexosomesinhibitsimmunecheckpointprogrammeddeathligand1andmetastaticprogressionofintrahepaticcholangiocarcinoma AT liuxiang liverkinaseb1inexosomesinhibitsimmunecheckpointprogrammeddeathligand1andmetastaticprogressionofintrahepaticcholangiocarcinoma AT lifeng liverkinaseb1inexosomesinhibitsimmunecheckpointprogrammeddeathligand1andmetastaticprogressionofintrahepaticcholangiocarcinoma AT jiangbin liverkinaseb1inexosomesinhibitsimmunecheckpointprogrammeddeathligand1andmetastaticprogressionofintrahepaticcholangiocarcinoma AT zhaoming liverkinaseb1inexosomesinhibitsimmunecheckpointprogrammeddeathligand1andmetastaticprogressionofintrahepaticcholangiocarcinoma AT matiexiang liverkinaseb1inexosomesinhibitsimmunecheckpointprogrammeddeathligand1andmetastaticprogressionofintrahepaticcholangiocarcinoma |